Pay in 4 interest-free payments of $6.56 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments
Insurance Coverage Predictions CagriSema (Advantage: Semaglutide Component): Leverages Wegovy's established coverage "Combination of proven medication + new molecule" easier sell to insurers Predicted coverage: 50-60% of commercial plans initially Retatrutide (Challenge: Novel Molecule): Entirely new drug class, no established coverage Higher efficacy but also higher side effects Will likely require trial-and-failure of cheaper options Predicted coverage: 40-50% of commercial plans initially Clinical Trial Populations and Indications CagriSema: Diabetes Focus REDEFINE-1: Obesity without diabetes (3,417 participants) REDEFINE-2: Obesity WITH type 2 diabetes (1,206 participants) REIMAGINE Program: Additional diabetes-focused trials Advantage: Strong diabetes data positions CagriSema for dual obesity + diabetes indications, like tirzepatide (Mounjaro/Zepbound)
Say goodbye to dullness and hello to a radiant, youthful appearance
Along with Semaglutide GLP-1, adopting dietary changes and regular physical activity is crucial to maximize its effectiveness and promote long-term wellness
US$ 26.82
US$ 20.07
US$ 25.49
